The MyMeds&Me team will be attending DIA Global Annual Meeting 2018 in Boston, USA 24-28 June. The Drug Information Association Annual Meeting has been a global platform for addressing challenges in healthcare for the last 50 years.
The conference is the longest running of its kind in the life sciences and will host more than 6,000 experts across the pharmaceutical, biotechnology and medical device industries from around the world. The conference will be an opportunity for leaders in the field to discuss the recent challenges and opportunities within science, healthcare and regulation.
Dr. Andrew Rut, Chief Executive Officer, MyMeds&Me said:
"The DIA Global Annual Meeting will provide the opportunity for healthcare leaders from across the world to discuss how tools, processes and people can be combined to transform how we manage the ongoing assessment of medicines. Adverse drug reactions are becoming a greater issue for healthcare systems as they are correlated with poor health outcomes and an avoidable misuse of resources. Deficiencies in data quality cannot be rectified by post-processing; data has to be obtained right first time at source. Pharmacovigilance platforms such as Reportum enable this by capturing purer data, faster and put patients at the forefront of safety procedures.”
Andy Watson, Chief Commercial Officer, MyMeds&Me said:
“DIA Global is an important international forum for MyMeds&Me to be part of the latest developments in the pharmacovigilance sector along with leading life science professionals from across the pharmaceutical industry. The meeting will highlight how pharma is changing the way in which it interacts with patients, combining advancements in technology with increased patient engagement to further safeguard the wellbeing of patients. Reportum has led the way in pharmacovigilance technology through transforming product complaint and adverse event report management by soliciting key information at source.”
MyMeds&Me will be at booth 2546 for the duration of DIA Boston 2018. MyMeds&Me will be attending FutureLink 2018 in Munich 6-7 June and the World Drug Safety Congress in Amsterdam 10-11 September.